The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.
|Articles|January 11, 2022
- Pharmaceutical Executive-01-01-2022
- Volume 42
- Issue 1
Our View on 2022: Pharm Exec’s Annual Industry Outlook
Advertisement
Articles in this issue
almost 5 years ago
Keeping Tabs on Quality: The Rise of Digitalalmost 5 years ago
China Invests in Building Biotechalmost 5 years ago
Branding Takes on a New Lookalmost 5 years ago
Addressing Access Burdensalmost 5 years ago
Meeting the Patient—Virtuallyalmost 5 years ago
The Age of Influencealmost 5 years ago
Boosting Immunotherapiesalmost 5 years ago
Pharma’s Psychedelic Experiencealmost 5 years ago
Supply Chain Procurementalmost 5 years ago
Breaking New Ground in BiopharmaAdvertisement
Related to this article
Advertisement
Advertisement
Trending on PharmExec
1
Hims & Hers Partners with Eli Lilly to Sell Obesity Medicines
2
FDA Grants Accelerated Approval to Rybrevant Faspro in Head and Neck Cancer
3
How Changes in a Tumor Have a Significant Impact on Treatment Options
4
The US Drug-Pricing Reset: Competing on Net Value
5